Table 2 Detailed information and characteristics of included studies
From: CT Scans and Cancer Risks: A Systematic Review and Dose-response Meta-analysis
Study | Study Type | Reason | CT scanner | NO. of CT scan (CT sites, participants) | Effective dose (mSv) | Cumulative dose (mSv) | Observation time | Follow-up (Y) | |
|---|---|---|---|---|---|---|---|---|---|
E | U | ||||||||
Burton [ 35], et al. 2018 | A | NA | NA | 1, 5655 ≥ 2, 204 | 10–44 | NA | 1995–2004 | 5.9 | 11.1 |
Nordenskjöld [ 10], et al. 2017 | A | NA | NA | NA | NA | NA | 1973–1992 | 22.5 | 21.9 |
Hung [ 36], et al. 2013 | A | CAD | NA | 1–5, 657 ≥ 6, 297 | NA | NA | 1997–2010 | 12 | 12 |
Olsen [ 54], et al. 2014 | A | CHD | NA | NA | NA | NA | 1977–2008 | 8 | 8 |
Shao [ 8], et al. 2020 | B | NA | NA | 1–3, 17,423 ≥ 4, 2742 | 0.5–17.0 | 0.5–71.3 | 2000–2013 | 9.3- 9.9 | 9.3- 9.9 |
Davis [ 11], et al. 2011 | B | NA | NA | 1–2, 98 ≥ 3, 30 | 2 | 1.5–10 | 2003.04–2007.12 | 2 | 2 |
Rampinelli [ 9], et al. 2017 | C | LCS | NA | NA | M: 1.0 F: 1.4 | M: 9.3 F: 13 | 2004–2015 | 10 | 10 |
Kritsaneepaiboon [ 37], et al. 2016 | NA | Multiple-injury | 64-multislice and 16-multislice CT, Phillips Brilliance | NA | NA | 19.43 ± 21.31 | 2013.01.01- 2013.12.31 | 1 | NA |
Griffey [ 38], et al. 2009 | C | Emergency | 64-multislice CT | NA | NA | 122 | 2005.06.01–2006.05.31 | 7.7 | NA |
Einstein [ 39], et al. 2008 | C | NA | Siemens AG 16-slice | NA | 8.8 ± 2.9 | NA | NA | NA | NA |
Faletra [ 40], et al. 2010 | C | Coronary disease | 64-slice CTCA | NA | Low: M 3.9 ± 1.7, F 3.1 ± 1.4 High: M 23.3 ± 4.0, F 22.3 ± 2.3 | NA | NA | NA | NA |
Niemann [ 41],et al 2013 | C | PE | Siemens Sensation 64;Siemens Sensation 16;Siemens Sensation 10 | NA | 4.35 ± 0.31 | NA | NA | 1 | NA |
Huang [ 42], et al. 2009 | NA | NA | 64-detector CT system (Discovery PET/CT,GE Healthcare, Milwaukee, Wis) | NA | M: 13.65, 24.80, 32.18 F: 13.45, 24.79, 31.91 | 100 | NA | NA | NA |
Perisinakis [ 43], et al. 2015 | D | NA | 256-slice CT | NA | 8.9 ± 0.9 | NA | NA | NA | NA |
Smith-Bindman [ 2], et al. 2009 | E | Various | NA | NA | 2–31 | NA | 2018.01.01–2018.05.30 | NA | NA |
Sodickson [ 44], et al. 2009 | A | Cysticfibrosis | NA | NA | NA | 54.3 | 1985–2007 | NA | NA |
Huang [ 45], et al. 2009 | D | NA | NA | NA | 45–73 | 100 | NA | NA | NA |
Huda [ 46], et al. 2010 | C | CAD | 64-MDCT scanner (Siemens Healthcare) | NA | 25.1 ± 4.9 | NA | NA | NA | NA |
Perisinakis [ 47], et al. 2012 | NA | NA | 256-slice TRO-CTA | NA | M: 3.8 ± 0.7 F: 6.5 ± 1.0 | NA | NA | NA | NA |
Einstein [ 48], et al. 2007 | NA | NA | 64-slice scanner (SOMATOM Sensation 64, Siemens AG, Munich, Germany) | NA | NA | lungs: 42–91 breast: 50–80 | NA | NA | NA |
Kim [ 49], et al. 2009 | NA | CAC | NA | NA | 3.1 | NA | 2000–2005 | NA | NA |
Majer [ 50], et al. 2018 | NA | NA | NA | NA | NA | 16–94 | NA | NA | NA |
Salibi [ 51], et al. 2014 | E | TBI | NA |  | NA | 87 ± 45 | NA | NA | NA |
Shah [ 52], et al. 2013 | C | Emergency | NA |  | 83.4 | NA | 2001.01–2007.12 | NA | NA |
Wylie [53], et al. 2018 | C | Hip Pain | NA |  | 30 | NA | 2015.01–2016.12 | NA | NA |